Log In
BCIQ
Print this Print this
 

Inspiolto Respimat, Spiolto Respimat, tiotropium/olodaterol (Stiolto Respimat)

Also known as: BI 1744/Spiriva, olodaterol/tiotropium

  Manage Alerts
Collapse Summary General Information
Company Boehringer Ingelheim GmbH
DescriptionOnce-daily fixed-dose combination of olodaterol, a long-acting beta 2 agonist (LABA), and Spiriva tiotropium, a long-acting muscarinic antagonist (LAMA)
Molecular Target Muscarinic receptor ; Adrenergic receptor beta 2 (ADRB2)
Mechanism of ActionAdrenergic receptor beta 2 (ADRB2) agonist; Muscarinic receptor antagonist
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentMarketed
Standard IndicationChronic obstructive pulmonary disease (COPD)
Indication DetailsTreat chronic obstructive pulmonary disease (COPD)
Regulatory Designation U.S. - Undisclosed Review (Treat chronic obstructive pulmonary disease (COPD))
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

08/30/2016

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today